The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 24, 2022
Filed:
Apr. 10, 2017
Applicant:
X4 Pharmaceuticals, Inc., Boston, MA (US);
Inventor:
Robert D. Arbeit, West Newton, MA (US);
Assignee:
X4 Pharmaceuticals, Inc., Boston, MA (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/4709 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); A61K 39/395 (2006.01); A61K 9/48 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4709 (2013.01); A61K 9/4808 (2013.01); A61K 38/1774 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 9/485 (2013.01); A61K 9/4866 (2013.01); A61K 2039/505 (2013.01);
Abstract
The present invention relates to methods of treating patients with advanced forms of cancer, such as unresectable or metastatic renal cell carcinoma or kidney cancer, in which X4P-001 or a pharmaceutically acceptable salt thereof is administered as monotherapy or in combination with an immune checkpoint inhibitor, such as nivolumab. The methods demonstrate surprising results, including regression of disease, with comparatively little toxicity.